Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05393895 · ClinicalTrials.gov registry record · Phase 3
An Evaluation of the Safety of CSF-1 in Presbyopic Subjects
A Phase 3 study, sponsored by Orasis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 178
- Enrollment target
NCT05393895 is a Phase 3 study that has completed, run by Orasis Pharmaceuticals. The registered enrollment target is 178 participants.
The verdict
NCT05393895, a Phase 3 study, has completed, sponsored by Orasis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 178 participants
- Enrollment target
Study Summary
This is a multi-center, double-masked, vehicle-controlled study. The purpose of the study is to evaluate the safety of CSF-1 compared with vehicle in presbyopic subjects. Subjects will be treated for at least 6 weeks.
Interventions
- DRUG Vehicle
- DRUG CSF-1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 178 participants |
| Start Date | 2022-04-22 |
| Est. Completion | 2022-12-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05393895
The ClinicalTrials.gov registry entry for NCT05393895 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 178 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Orasis Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle is the first listed.
NCT05393895 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05393895 about?
NCT05393895 is a clinical study titled "An Evaluation of the Safety of CSF-1 in Presbyopic Subjects". This is a multi-center, double-masked, vehicle-controlled study. The purpose of the study is to evaluate the safety of CSF-1 compared with vehicle in presbyopic subjects. Subjects will be treated for at least 6 weeks.
What is the current status of trial NCT05393895?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 178 participants. The study started on 2022-04-22. Estimated completion is 2022-12-01.
What interventions are being tested in trial NCT05393895?
The interventions under investigation include: Vehicle (DRUG), CSF-1 (DRUG).
Who is sponsoring clinical trial NCT05393895?
This trial is sponsored by Orasis Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.